Tag: MSO
-
Plus Products (PLUS.C) just parachuted right into my world
Heimark has a track record of rigorous market research prior to launching products. This research-based approach has reaped dividends in market penetration and revenue growth.
-
![Plus Products (PLUS.C): good deeds, good products, good numbers]()
Plus Products (PLUS.C): good deeds, good products, good numbers
“This will be the third year we have had the opportunity to partner with a local organization during pride month,” stated Mr. Heimark. “Last year we sold over 60,000 units and are looking forward to giving that record a run for its money this year.”
-
How Plus Products’ (PLUS.C) CEO Jake Heimark conquered California – and what he’s gonna do next
While the Noveau-riche cannabis bosses partied with company credit cards, Plus Products put its head down, did the researching, the strategizing, eventually building products that sold like hotcakes.
-
Cresco Labs (CL.C) reprices Origin House (OH.C) acquisition terms to match declining market
Cresco Labs (CL.C) and Origin House (OH.C) have updated the terms of their $1.1B acquisition, repricing the all-stock transaction to match declining share prices since the deal’s announcement in April. Pursuant to the Amendment, the consideration payable under the Arrangement will be reduced from 0.8428 of a subordinate voting share of Cresco Labs (a “Cresco…
-
Plus Products (PLUS.C) sheds short-term gain for long-term profitability in CPG segment
Plus Products (PLUS.C) is a proponent of the hyper-specialization approach in a sector which, at least once upon a time, prided itself on vertical integration across a wide swathe of products. The company operates in California and Nevada, selling their consumer packaged goods (CPG) edible products which include gummies, mints and more. A respectable cash…
-
What the FDA thinks of Curaleaf (CURA.C), the ‘world’s largest cannabis co.’
On July 22, 2019, the U.S. Food and Drug Administration (FDA) sent a warning letter to Curaleaf Holdings (CURA.C) via overnight delivery. The message was plain: Four of the company’s CBD-infused products are “in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act,” and Curaleaf’s CBD products for pets are “unapproved new…
